{"id":"W2898528000","doi":"10.1016/j.jtho.2018.08.635","title":"P1.01-79 CheckMate 817: Safety of Flat-Dose Nivolumab Plus Weight-Based Ipilimumab for the First-line (1L) Treatment of Advanced NSCLC","year":2018,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"ca_institutions":"Centre intégré universitaire de santé et de services sociaux de la Mauricie-et-du-Centre-du-Québec; Hôpital du Sacré-Cœur de Montréal","funders":"","keywords":"Medicine; Ipilimumab; Nivolumab; Regimen; Internal medicine; Oncology; Adverse effect; Cohort; Expanded access; Lung cancer; Clinical endpoint; Cancer; Clinical trial; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002807407,0.0003178504,0.0007633938,0.0001765726,0.0002421437,0.00066701,0.0004716534,0.0005900748,0.01430184],"category_scores_gemma":[0.000561925,0.000165694,0.0006816552,0.0001478053,0.0002459138,0.000424772,0.0001981734,0.001818255,0.002885749],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006151452,"about_ca_system_score_gemma":0.0007635473,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000925161,"about_ca_topic_score_gemma":0.002257587,"domain_scores_codex":[0.9998666,0.0000294232,0.000008601843,0.00002733577,0.0000274582,0.00004059595],"domain_scores_gemma":[0.9997962,0.00003835277,0.00003477099,0.00001915013,0.00002120151,0.00009025111],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.2995186,0.008683766,0.01311828,0.001456453,0.001543926,0.0006392733,0.00008647458,0.001768426,0.07072279,0.001191452,0.03361588,0.5676548],"study_design_scores_gemma":[0.2957166,0.3663029,0.1692823,0.0007092469,0.003797902,0.003699057,0.000135269,0.01033743,0.05211481,0.001528346,0.09618158,0.0001945837],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9700297,0.005939581,0.0004972501,0.001339841,0.0005652569,0.0005015092,0.003414323,0.0004422047,0.01727046],"genre_scores_gemma":[0.9853646,0.001463353,0.0005064398,0.001016686,0.0001581196,0.0001826783,0.003056357,0.00004096375,0.008210829],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01430184,"threshold_uncertainty_score":0.04784441,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0289928968762721,"score_gpt":0.3911550022582522,"score_spread":0.3621621053819801,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}